Menu
Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 16
The Ratio of Fibrinogen to Albumin is Related to the Occurrence of Retinopathy in Type 2 Diabetic Patients [Letter]
Authors Yang H, Zhang B, Huang S
Received 7 July 2023
Accepted for publication 18 July 2023
Published 21 July 2023 Volume 2023:16 Pages 2165—2166
DOI https://doi.org/10.2147/DMSO.S429497
Checked for plagiarism Yes
Editor who approved publication: Prof. Dr. Antonio Brunetti
Huiyan Yang,1 Bin Zhang,1 Shengqi Huang2
1Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of China; 2Department of Traditional Chinese Medicine, Yongning County People’s Hospital, Yongning, Ningxia, 750004, People’s Republic of China
Correspondence: Huiyan Yang, Email [email protected]
View the original paper by Ms Chen and colleagues
Dear editor
Recently, an original study titled “The Ratio of Fibrinogen to Albumin is Related to the Occurrence of Retinopathy in Type 2 Diabetic Patients”1 was published by Chen et al in the reputable journal “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy”. Firstly, I would like to congratulate the authors and acknowledge their successful publication.
The article concludes that fibrinogen to albumin ratio (FAR) is closely related to the development of DR in patients with T2DM, providing a basis for early detection, intervention and treatment of DR.
DR, its pathogenesis is not completely clear, most scholars believe that the occurrence of this disease and retinal micropathy related to damage to the vascular system.2 Studies have shown that factors such as high glucose and retinal hypoxia can stimulate the expression of vascular growth factor, reduce the release of neovascularization inhibitor factor, and thus induce the formation of neovascularization.3 Studies have shown that vascular endothelial growth factor (VEGF) is closely related to the formation and development of ocular neovascularization. Studies have shown that increased plasma viscosity and hypoxia are one of the main reasons leading to the high expression of VEGF.
Studies have shown4,5 that high levels of fibrinogen may contribute to vascular disease by increasing blood viscosity, stimulating fibrin formation, or increasing platelet interactions.
Our suspicion is that the relationship between fibrinogen level and albumin ratio and diabetic retinopathy needs to be further investigated.
However, there are some limitations of the current study. First, this study was a retrospective study of clinical cases with some selection bias, and the sample size of this study was small, which needs to be validated by multicenter, large sample, and prospective studies in the future. Second, the relationship between the inflammatory mechanism of diabetic retinopathy and FAR deserves further study. Finally, long-term clinical observation of fibrinogen may also provide more information on the prognosis of patients.
Disclosure
The authors report no conflicts of interest in this communication.
References
1. Chen X, Zhao J, You Y, Li Z, Chen S. The ratio of fibrinogen to albumin is related to the occurrence of retinopathy in type 2 diabetic patients. Diabetes Metab Syndr Obes. 2023;16:1859–1867. doi:10.2147/DMSO.S407391
2. Chen Y, Zhu X. Research on pathogenesis of visual reticulum disease in glycosuria has been advanced. Int J Ophthalmol. 2006;4:433–435.
3. Zhu D, Xu X. Research on the drug prevention and treatment of reticulum disease of glycosuria. Chin J Fundus Dis. 2006;1:66–69.
4. Weisel JW, Litvinov RL. Fibrin formation, structure and properties. In: [M]zfibrous Proteins: Structures and Mechanisms. Cham: Springer; 2017:405–456.
5. Mjelva R, Svingen GFT, Pedersen EKR, et al. Fibrinogen and neopterin is associated with future myocardial infarction and total mortality in patients with stable coronary artery disease. Thromb Haemost. 2018;47;(4):778–790.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.